Risk factor
Significant default risk
Profitability factor
Undervalued vs peers
About
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA, r
Target Price
The average target price of BION.SW is 48 and suggests 0% downside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Buy
Sell